Catalyst ligands

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

137076-54-1, To a solution of product 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (572.7 mg, 1 mmol) in dry DMF (15 ml), amino-maleinnide 137 (483.3 mg, 1 mmol) was added with HATU (272 mg, 1 .4 mmol) and DIPEA (360 mul, 1.84 mmol). The mixture was stirred overnight at room temperature. After removing the solvent under the vacuum, the crude product was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 90:10) to give compound tri-tert-butyl 2,2′,2″-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate as a white foam (396 mg, 57 %). Rf : 0.3 (CH2Cl2/MeOH, 90:10). 1H NMR (300MHz, CDCl3) delta 8.30 (b, 1 H, NH), 6.86 (s,2H, H6′), 3.78-3.54 (br, 4H, H3′, H4′), 3.54 (br, 4H, H13, H1′), 3.48 (br, 4H, H8), 3.09-2.99 (m, 8H, H2, H3), 2.97-2.86 (m, 8H, H5, H6), 1 .46 (s, 18H, H12), 1 .45 (s, 9H, H17). 13C NMR (75MHz, CDCl3) delta 171 .6 (C2′), 171 .0 (C5′), 170.4 (C9, C14), 134.2 (C6′), 81 .5 (C16), 81 .3 (C11), 57.8 (C1′), 55.7-55.2 (C8, C13), 54.1 – 51 .5 (C2, C3), 51 .0-48.9 (C5, C6), 38.0 (C4′), 32.7 (C3′), 27.8 (C17), 27.6 (C12). MS (ESI) : m/z 695 [M + H]+.

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; INSTITUT CURIE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); FLORENT, Jean-Claude; AIT SARKOUH, Rafik; JOHANNES, Ludger; SCHMIDT, Frederic; OBERLEITNER, Birgit; DRANSART, Estelle; SEMETEY, Vincent; WO2014/86942; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(7) To a mixture of compound (K6) (84.3 mg), tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (60.7 mg), DMF (1 mL), and DIEA (50 muL), HBTU (40.2 mg) was added, and the resulting mixture was stirred at room temperature for 30 minutes. Water (1 mL), methanol (0.5 mL), and formic acid (200 muL) were added thereto, and the mixture was purified by preparative HPLC to obtain compound (K7) (61.9 mg). LC/MS (ACQUITY) rt (min): 1.12 MS (ESI, m/z): 677.4 [M+2H]2+, 1351.3 [M-H]-, 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1119-97-7, MitMAB is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A 100mL round-bottom flask was equipped with a magnetic stir bar and a reflux condenser. To xylene (10.0mL), tetradecyltrimethylammonium bromide (1.1mmol) and a heterocyclic compound (1.0mmol) were added, followed bya solution of NaOH 50% (5.0 mL). The mixture was stirred at reflux temperature for 2-18 h. After completion of thereaction, the mixture was air-jet cooled to 25 C and TLC indicated the disappearance of the starting material. The reaction mix was treated with AcOEt (4 ¡Á 20 mL), and the organic phase separated and removed under reduced pressure. The residue was purified to analytical purity by column chromatography., 1119-97-7

As the paragraph descriping shows that 1119-97-7 is playing an increasingly important role.

Reference£º
Article; Gonzalez-Gonzalez, Carlos A.; Vega, Juan Javier Mejia; Monroy, Ricardo Garcia; Gonzalez-Calderon, Davir; Corona-Becerril, David; Fuentes-Benites, Aydee; Mascarua, Joaquin Tamariz; Gonzalez-Romero, Carlos; Journal of Chemistry; vol. 2017; (2017);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

Example 2 Preparation of 1,4-bis (trifluoroacetyl)-1,4,7-triazacyclononane 1,4,7-triazacyclononane (115.0 mg, 0.89 mmol) was dissolved in MeOH (2.0mL). To this clear solution was added NEt3 (0.13 mL, 0.89 mmol) in one portion, followed by ethyl trifluoroacetate (0.43 mL, 13.56 mmol) during a period of 5 minutes. Stirring was continued under N2 for 15 hours. Volatiles were then removed by rotavapor. The residue was dissolved in the minimum amount of CH2Cl2 (~2.0mL) and passed through a short silica gel pad, eluted with 100% EtOAc. The eluent was concentrated to give the product as a white solid (267.0 mg, 94%). 1H NMR (300 MHz, CDCl3): delta4.04-3.95 (multiplet, 2 H), 3.80-3.72 (multiplet, 2 H), 3.50-3.40 (multiplet, 4 H), 3.0-2.90 (multiplet, 4 H), 1.59 (singlet, 1 H). Mass calculated for C10H13F6N3O2 321.2, found M+1 322.1.

4730-54-5, The synthetic route of 4730-54-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Giandomenico, Christen M.; Yang, Wen; US2002/58807; (2002); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

2390-68-3, N-Decyl-N,N-dimethyldecan-1-aminium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Didceyldimethylammonium bromide (0.001 mol) was dissolved in 60 mL of distilled water by gentle heating and stirring. Sodium sulfacetamide (0.001 mol) was dissolved in 60 mL of distilled water by gentle heating and stirring. The two solutions were combined and the reaction mixture was heated and stirred for 30 minutes. The reaction mixture cooled to room temperature and then 60 mL of chloroform was added. The reaction mixture was stirred for an additional 30 minutes. The two phases were separated and the chloroform phase was washed several times with cool distilled water to remove any inorganic salt. The presence of chloride anions was monitored by silver nitrate test. A rotary evaporator removed the chloroform and a yellowish gel was obtained in 87.74% yield. 1H and 13C NMR (DMSO) were obtained. Melting point (hot plate apparatus)=25-30 C. Thermal data determined by thermalgravimetric analysis (TGA): Tonset5%=183.3 C. and Tonset=200.2 C., 2390-68-3

As the paragraph descriping shows that 2390-68-3 is playing an increasingly important role.

Reference£º
Patent; Rogers, Robin D.; Daly, Daniel T.; Swatloski, Richard P.; Hough, Whitney L.; Davis, James Hilliard; Smiglak, Marcin; Pernak, Juliusz; Spear, Scott K.; US2007/93462; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.167316-27-0,N-((1S,2S)-2-Amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide,as a common compound, the synthetic route is as follows.

Step 2 Scheme:- S, ? //–/N/ TEAF, I—) N 0 N 0 0 Compound 2 Compound 3 S-TsDPENMaterials : – Material Wt (g) MW Moles Equivs Compound 2 9 402. 79 0. 0224 1 DMF 39.5 73.09 0.54 24.16 (Rh Cp*C12) 2 0.0691 618.0 1. 12 x 104 5. 0 x 10-3 S, S-Ts DPEN 0.0817 366.0 2. 23 x 104 10. 0 x 10-3 DMF 7.5 73.09 0.103 4.59 TEAF 4. 65–2. 50 Cp* = pentamethylcyclopentadiene A 250 ML jacketed reactor set up with overhead stirrer, condenser, thermocouple and sparge pipe situated below the level of the agitator was assembled. The purified Compound 2 (9g) was charged to the reactor with DMF (39.5g). Freshly made catalyst (Rh CP*CI2) 2 (69.1 mg) and ligand S, S-Ts DPEN (N-p-toluenesulphonyl-1, 2- diphenylethylene-1, 2-diamine, 817 mg) in DMF (7.5g) was then charged. The contents were cooled to 10C and a nitrogen sparge rate of 1.2 L/min was established. The agitation was on full at 400 RPM. A solution of TEAF (triethylamine : formic acid mixture in 2: 5 mole ratio, 4.65 mis) was added drop-wise over 11.5 hrs overnight. The reaction was quenched with water (50MIS), a 15C exotherm (10-25C) was observed upon addition of the first 20 mis. The remaining 30 mis was added at <20C (bath temperature: 0C). Toluene was then charged (60 mis) at 20C. The reaction mass was agitated and allowed to settle respectively for 30 minutes each. The sparge was switched off at this point. The bottom red aqueous phase was back extracted with toluene (3X50M1S). The three resulting toluene phases were combined with the first black/brown organic phase. The combined reaction mass was concentrated down to a residual mass of 14.18g. The material obtained was then subjected to 3 repeats of the reduction and work up procedure, using freshly prepared catalyst for each repeat, to achieve 87% conversion, and a product mass of 7.8 g., 167316-27-0

167316-27-0 N-((1S,2S)-2-Amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide 6612782, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; AVECIA LIMITED; WO2005/28437; (2005); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4062-60-6,4062-60-6, N1,N2-Di-tert-butylethane-1,2-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Toluene (5 mL), secondary diamine (2a,b or 4-c) (1 mmol), paraformaldehyde or 4-fluorobenzaldehyde (2 mmol), alpha,omega-diacetylene (2 mmol), and CuCl (10 mol.%, 0.1 mg) were placed under argon into a Schlenk flask (10 mL) mounted on a magnetic stirrer, and the mixture was stirred for 8 h at 100 C under argon atmosphere.The resulting mixture was cooled, filtered through a layer ofsilica gel, dried over Na2SO4. The solvent was evaporated. The product was purified by column chromatography, the eluent is indicated in the description of the compound.

4062-60-6 N1,N2-Di-tert-butylethane-1,2-diamine 77680, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Khabibullina; Zaynullina; Tyumkina; Yanybin; Ibragimov; Russian Chemical Bulletin; vol. 68; 7; (2019); p. 1407 – 1413; Izv. Akad. Nauk, Ser. Khim.; 7; (2019); p. 1407 – 1413,7;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

57709-61-2, 1,10-Phenanthroline-2,9-dicarboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Under anhydrous conditions, 4-dimethylaminopyridine (DMAP,340 mg, 2.8 mmol, 2.5 equiv), N-(3-dimethylaminopropyl)-N?-ethylcarbodiimide hydrochloride (EDC¡¤HCl, 640 mg, 3.4 mmol,3.0 equiv), and 3-aminoquinoline (450 mg, 3.1 mmol, 2.8 equiv)were added as solids to a suspension of compound 3 (3.0¡¤102mg, 1.1 mmol, 1.0 equiv) in DMF (23 mL). The solution wasplaced under argon and stirred at room temperature (48 h). Theresulting yellow suspension was filtered under vacuum, and theisolated precipitate washed with saturated aqueous sodiumbicarbonate (30 mL), CH2Cl2 (20 mL), and diethyl ether (20 mL)to afford pure compound 4 as a pale yellow solid (490 mg, 85percent).1H NMR (300 MHz, DMSO-d6): delta = 7.68 (t, 3J = 7 Hz, 2 H), 7.75 (t,3J = 7 Hz, 2 H), 8.09?8.13 (m, 4 H), 8.33 (s, 2 H), 8.69 (d, 3J = 8 Hz,2 H), 8.91 (d, 3J = 8 Hz, 2 H), 9.17 (d, 4J = 2 Hz, 2 H), 9.68 (d, 4J = 2Hz, 2 H), 11.88 (s, 2 H); mp >280 ¡ãC (lit. >260 ¡ãC).7, 57709-61-2

As the paragraph descriping shows that 57709-61-2 is playing an increasingly important role.

Reference£º
Article; Miron, Caitlin E.; Petitjean, Anne; Synlett; vol. 29; 10; (2018); p. 1362 – 1366;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

To a DOTA-tra-tBu ester (28.6 mg, 0.05 mmol) in 2 mL DMF, DIPEA (24.8 mg, 0.192 mmol), HOBt (16.2 mg, 0.096 mmol), 43 (50 mg, 0.048 mmol) and EDCI (18.2 mg, 0.096 mmol) were added at 0 C. The mixture was stirred at room temperature for overnight, then 15 mL EtOAc was added to above solution. It was then washed with H20 (5 mL x 2) and brine (5 mL), dried over MgS04, and filtered. The filtrate was concentrated, and the residue was purified by FC (DCM/MeOH/NH4OH = 95/5/0.5) to give 43 as a colorless oil (yield: 26 mg, 35.6%): HRMS calcd. for C39H64N5Oio (1/2M + H)+: 762.4653, found 762.4787., 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; FIVE ELEVEN PHARMA INC.; KUNG, Hank F.; PLOESSL, Karl; CHOI, Seok Rye; ZHA, Zhihao; WU, Zehui; (131 pag.)WO2017/116994; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4479-74-7,4479-74-7, 2,2-Bipyridine-6,6-dicarboxylic Acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of Ca(NO3)2¡¤4H2O (60.0mg, 0.25mmol), H2BD (10.0mg, 0.04mmol) and 2.0mL DMF was sealed in a 10mL pressure-resistant glass tube, which was then heated to 100C within 100min and kept at 100C for 1440min followed by slowly cooled to 30C within 200min. Colourless crystals were obtained and washed with DMF and then dried in the air (yield: 71%. Based on Calcium.). Elemental Anal. Calc. for 1 C18H22CaN4O6: C, 44.12; H, 4.90; N, 13.72. Found: C, 44.51; H, 4.73; N, 12.23%. IR (KBr): 3460 (s), 2931 (w), 1660 (s), 1611 (s), 1548 (s), 1386 (s), 1255 (w), 1099 (m), 851 (w) 788 (s) 688 (s) 576 (w)cm-1.

As the paragraph descriping shows that 4479-74-7 is playing an increasingly important role.

Reference£º
Article; Wang, Yutong; Fan, Weidong; Wang, Xia; Liu, Di; Huang, Zhaodi; Dai, Fangna; Gao, Jing; Polyhedron; vol. 155; (2018); p. 261 – 267;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI